nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2D6—Hydroxyurea—head and neck cancer	0.147	0.327	CbGbCtD
Paroxetine—CYP2C8—Fluorouracil—head and neck cancer	0.0882	0.196	CbGbCtD
Paroxetine—CYP2C9—Fluorouracil—head and neck cancer	0.0615	0.137	CbGbCtD
Paroxetine—ABCB1—Vinblastine—head and neck cancer	0.0553	0.123	CbGbCtD
Paroxetine—CYP2D6—Vinblastine—head and neck cancer	0.0521	0.116	CbGbCtD
Paroxetine—ABCB1—Docetaxel—head and neck cancer	0.0456	0.101	CbGbCtD
Paroxetine—TACR1—trigeminal nerve—head and neck cancer	0.0242	0.26	CbGeAlD
Paroxetine—TACR1—cranial nerve—head and neck cancer	0.0172	0.185	CbGeAlD
Paroxetine—HTR2A—trigeminal nerve—head and neck cancer	0.00589	0.0634	CbGeAlD
Paroxetine—HTR2A—cranial nerve—head and neck cancer	0.0042	0.0452	CbGeAlD
Paroxetine—TACR1—connective tissue—head and neck cancer	0.00355	0.0382	CbGeAlD
Paroxetine—CHRM3—exocrine gland—head and neck cancer	0.00318	0.0343	CbGeAlD
Paroxetine—TACR1—trachea—head and neck cancer	0.00298	0.0321	CbGeAlD
Paroxetine—CHRM5—epithelium—head and neck cancer	0.00248	0.0267	CbGeAlD
Paroxetine—TACR1—head—head and neck cancer	0.00209	0.0225	CbGeAlD
Paroxetine—CHRM4—head—head and neck cancer	0.00197	0.0212	CbGeAlD
Paroxetine—CHRM1—parotid gland—head and neck cancer	0.00185	0.0199	CbGeAlD
Paroxetine—CHRM1—saliva-secreting gland—head and neck cancer	0.00177	0.0191	CbGeAlD
Paroxetine—CHRM3—saliva-secreting gland—head and neck cancer	0.00159	0.0171	CbGeAlD
Paroxetine—CHRM5—head—head and neck cancer	0.00154	0.0165	CbGeAlD
Paroxetine—TACR1—lymph node—head and neck cancer	0.00146	0.0158	CbGeAlD
Paroxetine—CHRM1—trachea—head and neck cancer	0.00137	0.0147	CbGeAlD
Paroxetine—HTR2A—neck—head and neck cancer	0.00121	0.013	CbGeAlD
Paroxetine—Pulmonary embolism—Docetaxel—head and neck cancer	0.00118	0.00298	CcSEcCtD
Paroxetine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00118	0.00298	CcSEcCtD
Paroxetine—Haemoglobin—Hydroxyurea—head and neck cancer	0.00114	0.00289	CcSEcCtD
Paroxetine—Haemorrhage—Hydroxyurea—head and neck cancer	0.00114	0.00288	CcSEcCtD
Paroxetine—Hallucination—Hydroxyurea—head and neck cancer	0.00113	0.00287	CcSEcCtD
Paroxetine—Colitis—Docetaxel—head and neck cancer	0.00113	0.00286	CcSEcCtD
Paroxetine—Candida infection—Docetaxel—head and neck cancer	0.00112	0.00284	CcSEcCtD
Paroxetine—Fluid retention—Docetaxel—head and neck cancer	0.00112	0.00283	CcSEcCtD
Paroxetine—Ataxia—Fluorouracil—head and neck cancer	0.00111	0.00282	CcSEcCtD
Paroxetine—Neuropathy—Docetaxel—head and neck cancer	0.0011	0.0028	CcSEcCtD
Paroxetine—Alopecia—Vinblastine—head and neck cancer	0.0011	0.00279	CcSEcCtD
Paroxetine—Dry skin—Fluorouracil—head and neck cancer	0.00108	0.00275	CcSEcCtD
Paroxetine—Oesophagitis—Docetaxel—head and neck cancer	0.00107	0.00272	CcSEcCtD
Paroxetine—Neoplasm—Docetaxel—head and neck cancer	0.00106	0.00269	CcSEcCtD
Paroxetine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00106	0.00268	CcSEcCtD
Paroxetine—CHRM2—head—head and neck cancer	0.00106	0.0114	CbGeAlD
Paroxetine—Lightheadedness—Docetaxel—head and neck cancer	0.00105	0.00267	CcSEcCtD
Paroxetine—SLC6A3—head—head and neck cancer	0.00105	0.0113	CbGeAlD
Paroxetine—Pulmonary oedema—Docetaxel—head and neck cancer	0.00105	0.00265	CcSEcCtD
Paroxetine—Muscular weakness—Fluorouracil—head and neck cancer	0.00104	0.00264	CcSEcCtD
Paroxetine—Angiopathy—Hydroxyurea—head and neck cancer	0.00103	0.00261	CcSEcCtD
Paroxetine—Dysphagia—Fluorouracil—head and neck cancer	0.00102	0.00259	CcSEcCtD
Paroxetine—Sepsis—Docetaxel—head and neck cancer	0.00102	0.00259	CcSEcCtD
Paroxetine—Chills—Hydroxyurea—head and neck cancer	0.00102	0.00258	CcSEcCtD
Paroxetine—Eosinophilia—Fluorouracil—head and neck cancer	0.00101	0.00256	CcSEcCtD
Paroxetine—Ill-defined disorder—Vinblastine—head and neck cancer	0.00101	0.00255	CcSEcCtD
Paroxetine—Alopecia—Hydroxyurea—head and neck cancer	0.001	0.00254	CcSEcCtD
Paroxetine—Anaemia—Vinblastine—head and neck cancer	0.001	0.00254	CcSEcCtD
Paroxetine—Angina pectoris—Fluorouracil—head and neck cancer	0.000996	0.00252	CcSEcCtD
Paroxetine—Phlebitis—Docetaxel—head and neck cancer	0.000991	0.00251	CcSEcCtD
Paroxetine—Erythema—Hydroxyurea—head and neck cancer	0.00099	0.00251	CcSEcCtD
Paroxetine—Thrombophlebitis—Docetaxel—head and neck cancer	0.000986	0.0025	CcSEcCtD
Paroxetine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000982	0.00249	CcSEcCtD
Paroxetine—Malaise—Vinblastine—head and neck cancer	0.000979	0.00248	CcSEcCtD
Paroxetine—Vertigo—Vinblastine—head and neck cancer	0.000975	0.00247	CcSEcCtD
Paroxetine—Leukopenia—Vinblastine—head and neck cancer	0.000972	0.00246	CcSEcCtD
Paroxetine—Pancytopenia—Fluorouracil—head and neck cancer	0.000971	0.00246	CcSEcCtD
Paroxetine—CHRM3—thyroid gland—head and neck cancer	0.000969	0.0104	CbGeAlD
Paroxetine—SLC6A4—head—head and neck cancer	0.000964	0.0104	CbGeAlD
Paroxetine—CHRM1—head—head and neck cancer	0.000961	0.0103	CbGeAlD
Paroxetine—Deafness—Docetaxel—head and neck cancer	0.000955	0.00242	CcSEcCtD
Paroxetine—Hepatic failure—Docetaxel—head and neck cancer	0.00095	0.00241	CcSEcCtD
Paroxetine—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000942	0.00238	CcSEcCtD
Paroxetine—Convulsion—Vinblastine—head and neck cancer	0.00094	0.00238	CcSEcCtD
Paroxetine—Hypertension—Vinblastine—head and neck cancer	0.000937	0.00237	CcSEcCtD
Paroxetine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000933	0.00236	CcSEcCtD
Paroxetine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000918	0.00233	CcSEcCtD
Paroxetine—Pneumonia—Fluorouracil—head and neck cancer	0.000917	0.00232	CcSEcCtD
Paroxetine—Anaemia—Hydroxyurea—head and neck cancer	0.000915	0.00232	CcSEcCtD
Paroxetine—Discomfort—Vinblastine—head and neck cancer	0.000913	0.00231	CcSEcCtD
Paroxetine—Visual disturbance—Docetaxel—head and neck cancer	0.000901	0.00228	CcSEcCtD
Paroxetine—Atrial fibrillation—Docetaxel—head and neck cancer	0.000901	0.00228	CcSEcCtD
Paroxetine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000899	0.00228	CcSEcCtD
Paroxetine—Renal impairment—Docetaxel—head and neck cancer	0.000897	0.00227	CcSEcCtD
Paroxetine—Myocardial infarction—Fluorouracil—head and neck cancer	0.000894	0.00226	CcSEcCtD
Paroxetine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000894	0.00226	CcSEcCtD
Paroxetine—Dermatitis bullous—Docetaxel—head and neck cancer	0.000893	0.00226	CcSEcCtD
Paroxetine—Malaise—Hydroxyurea—head and neck cancer	0.000893	0.00226	CcSEcCtD
Paroxetine—Stomatitis—Fluorouracil—head and neck cancer	0.000889	0.00225	CcSEcCtD
Paroxetine—Urinary tract infection—Fluorouracil—head and neck cancer	0.000886	0.00224	CcSEcCtD
Paroxetine—Conjunctivitis—Fluorouracil—head and neck cancer	0.000886	0.00224	CcSEcCtD
Paroxetine—Leukopenia—Hydroxyurea—head and neck cancer	0.000886	0.00224	CcSEcCtD
Paroxetine—Lethargy—Docetaxel—head and neck cancer	0.000871	0.00221	CcSEcCtD
Paroxetine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000867	0.0022	CcSEcCtD
Paroxetine—HTR2A—connective tissue—head and neck cancer	0.000866	0.00932	CbGeAlD
Paroxetine—Epistaxis—Fluorouracil—head and neck cancer	0.00086	0.00218	CcSEcCtD
Paroxetine—CHRM3—head—head and neck cancer	0.00086	0.00925	CbGeAlD
Paroxetine—Convulsion—Hydroxyurea—head and neck cancer	0.000858	0.00217	CcSEcCtD
Paroxetine—Hyponatraemia—Docetaxel—head and neck cancer	0.000857	0.00217	CcSEcCtD
Paroxetine—Sinusitis—Fluorouracil—head and neck cancer	0.000855	0.00217	CcSEcCtD
Paroxetine—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000854	0.00216	CcSEcCtD
Paroxetine—Agranulocytosis—Fluorouracil—head and neck cancer	0.000851	0.00215	CcSEcCtD
Paroxetine—SLC6A2—head—head and neck cancer	0.000849	0.00913	CbGeAlD
Paroxetine—Migraine—Docetaxel—head and neck cancer	0.00084	0.00213	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000837	0.00212	CcSEcCtD
Paroxetine—Discomfort—Hydroxyurea—head and neck cancer	0.000833	0.00211	CcSEcCtD
Paroxetine—Haemoglobin—Fluorouracil—head and neck cancer	0.000823	0.00208	CcSEcCtD
Paroxetine—HTR2A—epithelium—head and neck cancer	0.000822	0.00885	CbGeAlD
Paroxetine—Rhinitis—Fluorouracil—head and neck cancer	0.000821	0.00208	CcSEcCtD
Paroxetine—Haemorrhage—Fluorouracil—head and neck cancer	0.000818	0.00207	CcSEcCtD
Paroxetine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000814	0.00206	CcSEcCtD
Paroxetine—Pharyngitis—Fluorouracil—head and neck cancer	0.000812	0.00206	CcSEcCtD
Paroxetine—Oedema—Hydroxyurea—head and neck cancer	0.000808	0.00205	CcSEcCtD
Paroxetine—Ataxia—Docetaxel—head and neck cancer	0.000803	0.00203	CcSEcCtD
Paroxetine—Infection—Hydroxyurea—head and neck cancer	0.000803	0.00203	CcSEcCtD
Paroxetine—Paraesthesia—Vinblastine—head and neck cancer	0.000795	0.00201	CcSEcCtD
Paroxetine—Dehydration—Docetaxel—head and neck cancer	0.000794	0.00201	CcSEcCtD
Paroxetine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000792	0.00201	CcSEcCtD
Paroxetine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000791	0.002	CcSEcCtD
Paroxetine—Liver function test abnormal—Docetaxel—head and neck cancer	0.000788	0.002	CcSEcCtD
Paroxetine—Skin disorder—Hydroxyurea—head and neck cancer	0.000785	0.00199	CcSEcCtD
Paroxetine—Dry skin—Docetaxel—head and neck cancer	0.000783	0.00198	CcSEcCtD
Paroxetine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00078	0.00198	CcSEcCtD
Paroxetine—CYP2B6—lymphoid tissue—head and neck cancer	0.000776	0.00835	CbGeAlD
Paroxetine—Breast disorder—Docetaxel—head and neck cancer	0.000772	0.00195	CcSEcCtD
Paroxetine—Decreased appetite—Vinblastine—head and neck cancer	0.00077	0.00195	CcSEcCtD
Paroxetine—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000769	0.00195	CcSEcCtD
Paroxetine—Cramp muscle—Docetaxel—head and neck cancer	0.000769	0.00195	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000769	0.00195	CcSEcCtD
Paroxetine—Nasopharyngitis—Docetaxel—head and neck cancer	0.000764	0.00193	CcSEcCtD
Paroxetine—Constipation—Vinblastine—head and neck cancer	0.000758	0.00192	CcSEcCtD
Paroxetine—Pain—Vinblastine—head and neck cancer	0.000758	0.00192	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000753	0.00191	CcSEcCtD
Paroxetine—Dysphagia—Docetaxel—head and neck cancer	0.000738	0.00187	CcSEcCtD
Paroxetine—Arrhythmia—Fluorouracil—head and neck cancer	0.000731	0.00185	CcSEcCtD
Paroxetine—Feeling abnormal—Vinblastine—head and neck cancer	0.00073	0.00185	CcSEcCtD
Paroxetine—HTR2A—trachea—head and neck cancer	0.000727	0.00782	CbGeAlD
Paroxetine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000724	0.00183	CcSEcCtD
Paroxetine—Alopecia—Fluorouracil—head and neck cancer	0.000723	0.00183	CcSEcCtD
Paroxetine—Dyspnoea—Hydroxyurea—head and neck cancer	0.00072	0.00182	CcSEcCtD
Paroxetine—Angina pectoris—Docetaxel—head and neck cancer	0.000719	0.00182	CcSEcCtD
Paroxetine—Somnolence—Hydroxyurea—head and neck cancer	0.000718	0.00182	CcSEcCtD
Paroxetine—Erythema—Fluorouracil—head and neck cancer	0.000712	0.0018	CcSEcCtD
Paroxetine—Dyspepsia—Hydroxyurea—head and neck cancer	0.000711	0.0018	CcSEcCtD
Paroxetine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000702	0.00178	CcSEcCtD
Paroxetine—Pancytopenia—Docetaxel—head and neck cancer	0.000701	0.00178	CcSEcCtD
Paroxetine—Abdominal pain—Vinblastine—head and neck cancer	0.0007	0.00177	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000697	0.00177	CcSEcCtD
Paroxetine—Fatigue—Hydroxyurea—head and neck cancer	0.000696	0.00176	CcSEcCtD
Paroxetine—Pain—Hydroxyurea—head and neck cancer	0.000691	0.00175	CcSEcCtD
Paroxetine—Constipation—Hydroxyurea—head and neck cancer	0.000691	0.00175	CcSEcCtD
Paroxetine—Weight increased—Docetaxel—head and neck cancer	0.000672	0.0017	CcSEcCtD
Paroxetine—Vision blurred—Fluorouracil—head and neck cancer	0.000671	0.0017	CcSEcCtD
Paroxetine—Weight decreased—Docetaxel—head and neck cancer	0.000668	0.00169	CcSEcCtD
Paroxetine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000666	0.00169	CcSEcCtD
Paroxetine—Pneumonia—Docetaxel—head and neck cancer	0.000662	0.00168	CcSEcCtD
Paroxetine—Anaemia—Fluorouracil—head and neck cancer	0.000659	0.00167	CcSEcCtD
Paroxetine—Hypersensitivity—Vinblastine—head and neck cancer	0.000653	0.00165	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000652	0.00165	CcSEcCtD
Paroxetine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000649	0.00164	CcSEcCtD
Paroxetine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000645	0.00163	CcSEcCtD
Paroxetine—Myocardial infarction—Docetaxel—head and neck cancer	0.000645	0.00163	CcSEcCtD
Paroxetine—Stomatitis—Docetaxel—head and neck cancer	0.000641	0.00162	CcSEcCtD
Paroxetine—Jaundice—Docetaxel—head and neck cancer	0.000641	0.00162	CcSEcCtD
Paroxetine—Conjunctivitis—Docetaxel—head and neck cancer	0.00064	0.00162	CcSEcCtD
Paroxetine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000639	0.00162	CcSEcCtD
Paroxetine—Leukopenia—Fluorouracil—head and neck cancer	0.000638	0.00162	CcSEcCtD
Paroxetine—Asthenia—Vinblastine—head and neck cancer	0.000636	0.00161	CcSEcCtD
Paroxetine—CYP2B6—head—head and neck cancer	0.000626	0.00673	CbGeAlD
Paroxetine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000622	0.00158	CcSEcCtD
Paroxetine—Epistaxis—Docetaxel—head and neck cancer	0.000621	0.00157	CcSEcCtD
Paroxetine—Convulsion—Fluorouracil—head and neck cancer	0.000617	0.00156	CcSEcCtD
Paroxetine—Agranulocytosis—Docetaxel—head and neck cancer	0.000614	0.00156	CcSEcCtD
Paroxetine—Myalgia—Fluorouracil—head and neck cancer	0.000607	0.00154	CcSEcCtD
Paroxetine—Chest pain—Fluorouracil—head and neck cancer	0.000607	0.00154	CcSEcCtD
Paroxetine—Diarrhoea—Vinblastine—head and neck cancer	0.000606	0.00154	CcSEcCtD
Paroxetine—Discomfort—Fluorouracil—head and neck cancer	0.000599	0.00152	CcSEcCtD
Paroxetine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000595	0.00151	CcSEcCtD
Paroxetine—SLC6A2—lymph node—head and neck cancer	0.000594	0.0064	CbGeAlD
Paroxetine—Haemoglobin—Docetaxel—head and neck cancer	0.000594	0.0015	CcSEcCtD
Paroxetine—Rhinitis—Docetaxel—head and neck cancer	0.000592	0.0015	CcSEcCtD
Paroxetine—Hepatitis—Docetaxel—head and neck cancer	0.000591	0.0015	CcSEcCtD
Paroxetine—Haemorrhage—Docetaxel—head and neck cancer	0.000591	0.0015	CcSEcCtD
Paroxetine—Hypoaesthesia—Docetaxel—head and neck cancer	0.000588	0.00149	CcSEcCtD
Paroxetine—Confusional state—Fluorouracil—head and neck cancer	0.000586	0.00148	CcSEcCtD
Paroxetine—Pharyngitis—Docetaxel—head and neck cancer	0.000586	0.00148	CcSEcCtD
Paroxetine—Dizziness—Vinblastine—head and neck cancer	0.000586	0.00148	CcSEcCtD
Paroxetine—Oedema peripheral—Docetaxel—head and neck cancer	0.000582	0.00147	CcSEcCtD
Paroxetine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000581	0.00147	CcSEcCtD
Paroxetine—Oedema—Fluorouracil—head and neck cancer	0.000581	0.00147	CcSEcCtD
Paroxetine—Connective tissue disorder—Docetaxel—head and neck cancer	0.00058	0.00147	CcSEcCtD
Paroxetine—Asthenia—Hydroxyurea—head and neck cancer	0.00058	0.00147	CcSEcCtD
Paroxetine—Infection—Fluorouracil—head and neck cancer	0.000578	0.00146	CcSEcCtD
Paroxetine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00057	0.00144	CcSEcCtD
Paroxetine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000569	0.00144	CcSEcCtD
Paroxetine—Visual impairment—Docetaxel—head and neck cancer	0.000569	0.00144	CcSEcCtD
Paroxetine—Tachycardia—Fluorouracil—head and neck cancer	0.000568	0.00144	CcSEcCtD
Paroxetine—Vomiting—Vinblastine—head and neck cancer	0.000563	0.00143	CcSEcCtD
Paroxetine—Erythema multiforme—Docetaxel—head and neck cancer	0.000559	0.00141	CcSEcCtD
Paroxetine—Headache—Vinblastine—head and neck cancer	0.000555	0.00141	CcSEcCtD
Paroxetine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000553	0.0014	CcSEcCtD
Paroxetine—Eye disorder—Docetaxel—head and neck cancer	0.000552	0.0014	CcSEcCtD
Paroxetine—Flushing—Docetaxel—head and neck cancer	0.000548	0.00139	CcSEcCtD
Paroxetine—Cardiac disorder—Docetaxel—head and neck cancer	0.000548	0.00139	CcSEcCtD
Paroxetine—Hypotension—Fluorouracil—head and neck cancer	0.000543	0.00138	CcSEcCtD
Paroxetine—ABCB1—epithelium—head and neck cancer	0.000539	0.0058	CbGeAlD
Paroxetine—Angiopathy—Docetaxel—head and neck cancer	0.000536	0.00136	CcSEcCtD
Paroxetine—Dizziness—Hydroxyurea—head and neck cancer	0.000534	0.00135	CcSEcCtD
Paroxetine—Immune system disorder—Docetaxel—head and neck cancer	0.000534	0.00135	CcSEcCtD
Paroxetine—Mediastinal disorder—Docetaxel—head and neck cancer	0.000532	0.00135	CcSEcCtD
Paroxetine—Chills—Docetaxel—head and neck cancer	0.00053	0.00134	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00053	0.00134	CcSEcCtD
Paroxetine—Arrhythmia—Docetaxel—head and neck cancer	0.000528	0.00134	CcSEcCtD
Paroxetine—Nausea—Vinblastine—head and neck cancer	0.000526	0.00133	CcSEcCtD
Paroxetine—Insomnia—Fluorouracil—head and neck cancer	0.000526	0.00133	CcSEcCtD
Paroxetine—Paraesthesia—Fluorouracil—head and neck cancer	0.000522	0.00132	CcSEcCtD
Paroxetine—Alopecia—Docetaxel—head and neck cancer	0.000522	0.00132	CcSEcCtD
Paroxetine—Dyspnoea—Fluorouracil—head and neck cancer	0.000518	0.00131	CcSEcCtD
Paroxetine—Mental disorder—Docetaxel—head and neck cancer	0.000518	0.00131	CcSEcCtD
Paroxetine—Somnolence—Fluorouracil—head and neck cancer	0.000517	0.00131	CcSEcCtD
Paroxetine—Erythema—Docetaxel—head and neck cancer	0.000514	0.0013	CcSEcCtD
Paroxetine—Malnutrition—Docetaxel—head and neck cancer	0.000514	0.0013	CcSEcCtD
Paroxetine—Vomiting—Hydroxyurea—head and neck cancer	0.000514	0.0013	CcSEcCtD
Paroxetine—Dyspepsia—Fluorouracil—head and neck cancer	0.000512	0.0013	CcSEcCtD
Paroxetine—HTR2A—head—head and neck cancer	0.00051	0.00549	CbGeAlD
Paroxetine—Rash—Hydroxyurea—head and neck cancer	0.000509	0.00129	CcSEcCtD
Paroxetine—Dermatitis—Hydroxyurea—head and neck cancer	0.000509	0.00129	CcSEcCtD
Paroxetine—Headache—Hydroxyurea—head and neck cancer	0.000506	0.00128	CcSEcCtD
Paroxetine—Decreased appetite—Fluorouracil—head and neck cancer	0.000505	0.00128	CcSEcCtD
Paroxetine—Dysgeusia—Docetaxel—head and neck cancer	0.000504	0.00128	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000502	0.00127	CcSEcCtD
Paroxetine—Back pain—Docetaxel—head and neck cancer	0.000497	0.00126	CcSEcCtD
Paroxetine—Pain—Fluorouracil—head and neck cancer	0.000497	0.00126	CcSEcCtD
Paroxetine—Muscle spasms—Docetaxel—head and neck cancer	0.000494	0.00125	CcSEcCtD
Paroxetine—Nausea—Hydroxyurea—head and neck cancer	0.00048	0.00122	CcSEcCtD
Paroxetine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000479	0.00121	CcSEcCtD
Paroxetine—ABCB1—trachea—head and neck cancer	0.000476	0.00513	CbGeAlD
Paroxetine—Anaemia—Docetaxel—head and neck cancer	0.000475	0.0012	CcSEcCtD
Paroxetine—CYP2D6—head—head and neck cancer	0.000465	0.005	CbGeAlD
Paroxetine—Urticaria—Fluorouracil—head and neck cancer	0.000462	0.00117	CcSEcCtD
Paroxetine—Syncope—Docetaxel—head and neck cancer	0.000461	0.00117	CcSEcCtD
Paroxetine—Leukopenia—Docetaxel—head and neck cancer	0.00046	0.00117	CcSEcCtD
Paroxetine—Body temperature increased—Fluorouracil—head and neck cancer	0.00046	0.00116	CcSEcCtD
Paroxetine—Palpitations—Docetaxel—head and neck cancer	0.000454	0.00115	CcSEcCtD
Paroxetine—Loss of consciousness—Docetaxel—head and neck cancer	0.000452	0.00114	CcSEcCtD
Paroxetine—Cough—Docetaxel—head and neck cancer	0.000449	0.00114	CcSEcCtD
Paroxetine—Convulsion—Docetaxel—head and neck cancer	0.000446	0.00113	CcSEcCtD
Paroxetine—Hypertension—Docetaxel—head and neck cancer	0.000444	0.00112	CcSEcCtD
Paroxetine—Arthralgia—Docetaxel—head and neck cancer	0.000438	0.00111	CcSEcCtD
Paroxetine—Chest pain—Docetaxel—head and neck cancer	0.000438	0.00111	CcSEcCtD
Paroxetine—Myalgia—Docetaxel—head and neck cancer	0.000438	0.00111	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000435	0.0011	CcSEcCtD
Paroxetine—Hypersensitivity—Fluorouracil—head and neck cancer	0.000428	0.00109	CcSEcCtD
Paroxetine—Dry mouth—Docetaxel—head and neck cancer	0.000428	0.00108	CcSEcCtD
Paroxetine—Confusional state—Docetaxel—head and neck cancer	0.000423	0.00107	CcSEcCtD
Paroxetine—Oedema—Docetaxel—head and neck cancer	0.00042	0.00106	CcSEcCtD
Paroxetine—Anaphylactic shock—Docetaxel—head and neck cancer	0.00042	0.00106	CcSEcCtD
Paroxetine—Infection—Docetaxel—head and neck cancer	0.000417	0.00106	CcSEcCtD
Paroxetine—ABCB1—lymphoid tissue—head and neck cancer	0.000415	0.00446	CbGeAlD
Paroxetine—Shock—Docetaxel—head and neck cancer	0.000413	0.00105	CcSEcCtD
Paroxetine—Nervous system disorder—Docetaxel—head and neck cancer	0.000412	0.00104	CcSEcCtD
Paroxetine—Pruritus—Fluorouracil—head and neck cancer	0.000411	0.00104	CcSEcCtD
Paroxetine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000411	0.00104	CcSEcCtD
Paroxetine—Tachycardia—Docetaxel—head and neck cancer	0.00041	0.00104	CcSEcCtD
Paroxetine—Skin disorder—Docetaxel—head and neck cancer	0.000408	0.00103	CcSEcCtD
Paroxetine—Diarrhoea—Fluorouracil—head and neck cancer	0.000398	0.00101	CcSEcCtD
Paroxetine—Hypotension—Docetaxel—head and neck cancer	0.000392	0.000993	CcSEcCtD
Paroxetine—Dizziness—Fluorouracil—head and neck cancer	0.000385	0.000974	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000382	0.000968	CcSEcCtD
Paroxetine—Insomnia—Docetaxel—head and neck cancer	0.00038	0.000961	CcSEcCtD
Paroxetine—ABCB1—thyroid gland—head and neck cancer	0.000377	0.00405	CbGeAlD
Paroxetine—Paraesthesia—Docetaxel—head and neck cancer	0.000377	0.000954	CcSEcCtD
Paroxetine—Dyspnoea—Docetaxel—head and neck cancer	0.000374	0.000948	CcSEcCtD
Paroxetine—Somnolence—Docetaxel—head and neck cancer	0.000373	0.000945	CcSEcCtD
Paroxetine—Vomiting—Fluorouracil—head and neck cancer	0.00037	0.000936	CcSEcCtD
Paroxetine—Dyspepsia—Docetaxel—head and neck cancer	0.000369	0.000936	CcSEcCtD
Paroxetine—Rash—Fluorouracil—head and neck cancer	0.000367	0.000929	CcSEcCtD
Paroxetine—Dermatitis—Fluorouracil—head and neck cancer	0.000366	0.000928	CcSEcCtD
Paroxetine—Decreased appetite—Docetaxel—head and neck cancer	0.000365	0.000924	CcSEcCtD
Paroxetine—Headache—Fluorouracil—head and neck cancer	0.000364	0.000923	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000362	0.000918	CcSEcCtD
Paroxetine—Fatigue—Docetaxel—head and neck cancer	0.000362	0.000916	CcSEcCtD
Paroxetine—Pain—Docetaxel—head and neck cancer	0.000359	0.000909	CcSEcCtD
Paroxetine—Constipation—Docetaxel—head and neck cancer	0.000359	0.000909	CcSEcCtD
Paroxetine—Feeling abnormal—Docetaxel—head and neck cancer	0.000346	0.000876	CcSEcCtD
Paroxetine—Nausea—Fluorouracil—head and neck cancer	0.000345	0.000875	CcSEcCtD
Paroxetine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000343	0.000869	CcSEcCtD
Paroxetine—ABCB1—head—head and neck cancer	0.000334	0.0036	CbGeAlD
Paroxetine—Body temperature increased—Docetaxel—head and neck cancer	0.000332	0.00084	CcSEcCtD
Paroxetine—Abdominal pain—Docetaxel—head and neck cancer	0.000332	0.00084	CcSEcCtD
Paroxetine—Hypersensitivity—Docetaxel—head and neck cancer	0.000309	0.000783	CcSEcCtD
Paroxetine—Asthenia—Docetaxel—head and neck cancer	0.000301	0.000763	CcSEcCtD
Paroxetine—Pruritus—Docetaxel—head and neck cancer	0.000297	0.000752	CcSEcCtD
Paroxetine—Diarrhoea—Docetaxel—head and neck cancer	0.000287	0.000727	CcSEcCtD
Paroxetine—Dizziness—Docetaxel—head and neck cancer	0.000278	0.000703	CcSEcCtD
Paroxetine—Vomiting—Docetaxel—head and neck cancer	0.000267	0.000676	CcSEcCtD
Paroxetine—Rash—Docetaxel—head and neck cancer	0.000265	0.00067	CcSEcCtD
Paroxetine—Dermatitis—Docetaxel—head and neck cancer	0.000264	0.00067	CcSEcCtD
Paroxetine—Headache—Docetaxel—head and neck cancer	0.000263	0.000666	CcSEcCtD
Paroxetine—Nausea—Docetaxel—head and neck cancer	0.000249	0.000631	CcSEcCtD
Paroxetine—ABCB1—lymph node—head and neck cancer	0.000234	0.00252	CbGeAlD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	4.49e-05	0.00072	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—GRP—head and neck cancer	4.43e-05	0.00071	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—GRP—head and neck cancer	4.41e-05	0.000706	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—GRP—head and neck cancer	4.39e-05	0.000704	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—HRAS—head and neck cancer	4.36e-05	0.000698	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—GRP—head and neck cancer	4.35e-05	0.000697	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT6—head and neck cancer	4.3e-05	0.000689	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT6—head and neck cancer	4.28e-05	0.000686	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT6—head and neck cancer	4.26e-05	0.000684	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—PIK3CA—head and neck cancer	4.26e-05	0.000683	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	4.24e-05	0.00068	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT6—head and neck cancer	4.22e-05	0.000677	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	4.22e-05	0.000676	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	4.21e-05	0.000674	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	4.2e-05	0.000672	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.15e-05	0.000666	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—DPYD—head and neck cancer	4.09e-05	0.000656	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	4.06e-05	0.000651	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—NAT2—head and neck cancer	3.95e-05	0.000633	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—HRAS—head and neck cancer	3.94e-05	0.000632	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—YAP1—head and neck cancer	3.88e-05	0.000622	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	3.84e-05	0.000615	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—AKT1—head and neck cancer	3.83e-05	0.000615	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—YAP1—head and neck cancer	3.81e-05	0.00061	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL2—head and neck cancer	3.79e-05	0.000608	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—YAP1—head and neck cancer	3.79e-05	0.000607	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—YAP1—head and neck cancer	3.77e-05	0.000605	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—YAP1—head and neck cancer	3.74e-05	0.000599	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—CCND1—head and neck cancer	3.7e-05	0.000593	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	3.65e-05	0.000586	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	3.65e-05	0.000586	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PTEN—head and neck cancer	3.57e-05	0.000572	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—AKT1—head and neck cancer	3.48e-05	0.000558	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—DPYD—head and neck cancer	3.46e-05	0.000555	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—NAT2—head and neck cancer	3.44e-05	0.000552	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.41e-05	0.000547	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.38e-05	0.000542	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—YAP1—head and neck cancer	3.29e-05	0.000527	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—IL2—head and neck cancer	3.25e-05	0.00052	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—NAT2—head and neck cancer	3.24e-05	0.00052	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—VEGFA—head and neck cancer	3.22e-05	0.000517	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—NAT2—head and neck cancer	3.22e-05	0.000515	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—STAT3—head and neck cancer	3.19e-05	0.000512	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	3.17e-05	0.000508	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—IL2—head and neck cancer	3.11e-05	0.000498	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.07e-05	0.000492	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MAPK3—head and neck cancer	3.05e-05	0.000489	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DPYD—head and neck cancer	3.02e-05	0.000484	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL2—head and neck cancer	2.95e-05	0.000473	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MAPK1—head and neck cancer	2.9e-05	0.000465	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EGFR—head and neck cancer	2.9e-05	0.000465	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—YAP1—head and neck cancer	2.86e-05	0.000459	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DPYD—head and neck cancer	2.84e-05	0.000456	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL2—head and neck cancer	2.82e-05	0.000453	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DPYD—head and neck cancer	2.82e-05	0.000452	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—TYMS—head and neck cancer	2.71e-05	0.000434	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—YAP1—head and neck cancer	2.7e-05	0.000433	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GSTM1—head and neck cancer	2.68e-05	0.000429	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—YAP1—head and neck cancer	2.68e-05	0.000429	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	2.59e-05	0.000415	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GPX1—head and neck cancer	2.57e-05	0.000411	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP1A1—head and neck cancer	2.54e-05	0.000407	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NOTCH1—head and neck cancer	2.53e-05	0.000406	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PIK3CA—head and neck cancer	2.52e-05	0.000404	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.47e-05	0.000396	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—head and neck cancer	2.44e-05	0.00039	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NOTCH1—head and neck cancer	2.42e-05	0.000388	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—MAPK3—head and neck cancer	2.37e-05	0.00038	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—TYMS—head and neck cancer	2.33e-05	0.000374	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—head and neck cancer	2.33e-05	0.000373	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GSTM1—head and neck cancer	2.3e-05	0.000369	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—MAPK3—head and neck cancer	2.27e-05	0.000364	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—MAPK1—head and neck cancer	2.26e-05	0.000361	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EGFR—head and neck cancer	2.25e-05	0.000361	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GPX1—head and neck cancer	2.21e-05	0.000354	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—IL2—head and neck cancer	2.2e-05	0.000353	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—IL2—head and neck cancer	2.19e-05	0.000351	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP1A1—head and neck cancer	2.18e-05	0.00035	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—IL2—head and neck cancer	2.18e-05	0.00035	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—IL2—head and neck cancer	2.16e-05	0.000346	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—MAPK1—head and neck cancer	2.16e-05	0.000346	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EGFR—head and neck cancer	2.16e-05	0.000346	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—PIK3CA—head and neck cancer	2.15e-05	0.000345	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.15e-05	0.000345	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—PIK3CA—head and neck cancer	2.06e-05	0.000331	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—head and neck cancer	2.06e-05	0.00033	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.01e-05	0.000322	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL2—head and neck cancer	2e-05	0.00032	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL2—head and neck cancer	1.99e-05	0.000319	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL2—head and neck cancer	1.98e-05	0.000318	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TYMS—head and neck cancer	1.97e-05	0.000316	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL2—head and neck cancer	1.96e-05	0.000315	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PIK3CA—head and neck cancer	1.96e-05	0.000314	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GSTM1—head and neck cancer	1.95e-05	0.000313	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PIK3CA—head and neck cancer	1.87e-05	0.0003	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—head and neck cancer	1.87e-05	0.000299	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP1A1—head and neck cancer	1.85e-05	0.000296	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—head and neck cancer	1.81e-05	0.00029	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—head and neck cancer	1.76e-05	0.000282	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.75e-05	0.000281	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL2—head and neck cancer	1.74e-05	0.000279	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—head and neck cancer	1.73e-05	0.000278	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TYMS—head and neck cancer	1.72e-05	0.000276	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NOTCH1—head and neck cancer	1.72e-05	0.000275	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NOTCH1—head and neck cancer	1.71e-05	0.000274	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NOTCH1—head and neck cancer	1.7e-05	0.000273	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GSTM1—head and neck cancer	1.7e-05	0.000272	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCND1—head and neck cancer	1.7e-05	0.000272	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—head and neck cancer	1.69e-05	0.00027	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NOTCH1—head and neck cancer	1.68e-05	0.00027	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL2—head and neck cancer	1.67e-05	0.000267	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—head and neck cancer	1.64e-05	0.000263	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—head and neck cancer	1.63e-05	0.000261	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCND1—head and neck cancer	1.63e-05	0.000261	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TYMS—head and neck cancer	1.62e-05	0.00026	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.61e-05	0.000258	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK3—head and neck cancer	1.61e-05	0.000258	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TYMS—head and neck cancer	1.61e-05	0.000257	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.6e-05	0.000257	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—head and neck cancer	1.6e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK3—head and neck cancer	1.6e-05	0.000256	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK3—head and neck cancer	1.59e-05	0.000255	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.59e-05	0.000255	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK3—head and neck cancer	1.58e-05	0.000253	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—head and neck cancer	1.57e-05	0.000252	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—head and neck cancer	1.53e-05	0.000246	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—head and neck cancer	1.53e-05	0.000245	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	1.53e-05	0.000245	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	1.53e-05	0.000245	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—head and neck cancer	1.52e-05	0.000244	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—MAPK1—head and neck cancer	1.52e-05	0.000244	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—head and neck cancer	1.52e-05	0.000244	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.52e-05	0.000244	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.52e-05	0.000243	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—MAPK1—head and neck cancer	1.52e-05	0.000243	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—head and neck cancer	1.52e-05	0.000243	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—head and neck cancer	1.51e-05	0.000242	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.51e-05	0.000241	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—MAPK1—head and neck cancer	1.5e-05	0.000241	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—head and neck cancer	1.5e-05	0.000241	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—head and neck cancer	1.48e-05	0.000237	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—STAT3—head and neck cancer	1.47e-05	0.000235	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.46e-05	0.000234	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.45e-05	0.000233	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—head and neck cancer	1.45e-05	0.000232	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—head and neck cancer	1.43e-05	0.00023	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—head and neck cancer	1.42e-05	0.000227	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—STAT3—head and neck cancer	1.4e-05	0.000225	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK3—head and neck cancer	1.4e-05	0.000224	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK3—head and neck cancer	1.34e-05	0.000215	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MAPK1—head and neck cancer	1.33e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—head and neck cancer	1.33e-05	0.000213	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.33e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—head and neck cancer	1.32e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—head and neck cancer	1.32e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—head and neck cancer	1.32e-05	0.000211	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—head and neck cancer	1.3e-05	0.000209	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—head and neck cancer	1.3e-05	0.000208	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MAPK1—head and neck cancer	1.28e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—head and neck cancer	1.28e-05	0.000204	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.24e-05	0.000198	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.23e-05	0.000197	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	1.22e-05	0.000196	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—head and neck cancer	1.22e-05	0.000195	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—head and neck cancer	1.21e-05	0.000193	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.19e-05	0.000191	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.19e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—head and neck cancer	1.18e-05	0.00019	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.18e-05	0.000189	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL2—head and neck cancer	1.17e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—head and neck cancer	1.17e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL2—head and neck cancer	1.17e-05	0.000188	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL2—head and neck cancer	1.16e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—head and neck cancer	1.16e-05	0.000185	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.15e-05	0.000184	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCND1—head and neck cancer	1.14e-05	0.000183	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCND1—head and neck cancer	1.14e-05	0.000183	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—head and neck cancer	1.13e-05	0.000182	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCND1—head and neck cancer	1.13e-05	0.000181	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—head and neck cancer	1.12e-05	0.000179	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.11e-05	0.000178	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—head and neck cancer	1.11e-05	0.000177	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—head and neck cancer	1.1e-05	0.000177	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—head and neck cancer	1.1e-05	0.000177	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—head and neck cancer	1.1e-05	0.000176	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—head and neck cancer	1.09e-05	0.000175	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.08e-05	0.000174	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	1.08e-05	0.000173	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—head and neck cancer	1.07e-05	0.000172	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—head and neck cancer	1.07e-05	0.000172	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—head and neck cancer	1.07e-05	0.000171	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—head and neck cancer	1.06e-05	0.000171	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—head and neck cancer	1.02e-05	0.000164	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	1e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	9.98e-06	0.00016	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—head and neck cancer	9.95e-06	0.000159	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	9.93e-06	0.000159	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STAT3—head and neck cancer	9.88e-06	0.000158	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—head and neck cancer	9.85e-06	0.000158	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STAT3—head and neck cancer	9.85e-06	0.000158	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STAT3—head and neck cancer	9.75e-06	0.000156	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—head and neck cancer	9.59e-06	0.000154	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—head and neck cancer	9.58e-06	0.000154	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	9.49e-06	0.000152	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—head and neck cancer	9.44e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	9.44e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK3—head and neck cancer	9.41e-06	0.000151	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK3—head and neck cancer	9.32e-06	0.000149	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—head and neck cancer	9.29e-06	0.000149	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—head and neck cancer	9.04e-06	0.000145	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	9.03e-06	0.000145	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—head and neck cancer	9.03e-06	0.000145	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	9.03e-06	0.000145	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	8.98e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—head and neck cancer	8.98e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MAPK1—head and neck cancer	8.95e-06	0.000144	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—head and neck cancer	8.95e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—head and neck cancer	8.95e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MAPK1—head and neck cancer	8.87e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—head and neck cancer	8.87e-06	0.000142	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—head and neck cancer	8.36e-06	0.000134	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—head and neck cancer	7.99e-06	0.000128	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—head and neck cancer	7.88e-06	0.000126	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	7.84e-06	0.000126	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—head and neck cancer	7.81e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	7.79e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—head and neck cancer	7.77e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—head and neck cancer	7.69e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—head and neck cancer	7.59e-06	0.000122	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—head and neck cancer	7.58e-06	0.000122	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—head and neck cancer	7.54e-06	0.000121	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—head and neck cancer	7.52e-06	0.00012	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—head and neck cancer	7.44e-06	0.000119	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	7.25e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—head and neck cancer	7.21e-06	0.000116	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—head and neck cancer	7.19e-06	0.000115	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—head and neck cancer	7.12e-06	0.000114	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—head and neck cancer	6.77e-06	0.000108	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—head and neck cancer	6.53e-06	0.000105	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	6.4e-06	0.000103	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—head and neck cancer	6.37e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—head and neck cancer	6.35e-06	0.000102	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—head and neck cancer	6.29e-06	0.000101	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—head and neck cancer	5.9e-06	9.45e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	5.56e-06	8.91e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—head and neck cancer	5.53e-06	8.86e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	5.51e-06	8.83e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—head and neck cancer	4.82e-06	7.72e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—head and neck cancer	4.54e-06	7.27e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—head and neck cancer	4.5e-06	7.21e-05	CbGpPWpGaD
